PLK4 and neoplasm: The authors found that PARP inhibitor talazoparib-induced lncRNA-PLK4 suppressed proliferation of HCC cells and tumor growth in a xenograft model through YAP inhibition, indicating a tumor-suppressive axis that could be leveraged therapeutically [47].